Chimeric Therapeutics Limited
CHMMF
$0.001
-$0.029-96.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -83.40% | -44.16% | 60.22% | 87.89% | 109.57% |
| Total Revenue | -83.40% | -44.16% | 60.22% | 87.89% | 109.57% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -83.40% | -44.16% | 60.22% | 87.89% | 109.57% |
| SG&A Expenses | -30.74% | -34.29% | -38.08% | -24.26% | -7.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.93% | -25.36% | -31.53% | -16.32% | 4.60% |
| Operating Income | -48.12% | 16.79% | 48.05% | 41.81% | 31.23% |
| Income Before Tax | -44.40% | 21.32% | 52.54% | 45.44% | 33.93% |
| Income Tax Expenses | 362.16% | 2,853.85% | -89.23% | -119.58% | -129.55% |
| Earnings from Continuing Operations | -47.23% | 20.72% | 52.67% | 46.06% | 35.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.23% | 20.72% | 52.67% | 46.06% | 35.39% |
| EBIT | -48.12% | 16.79% | 48.05% | 41.81% | 31.23% |
| EBITDA | -51.52% | 18.31% | 50.36% | 43.98% | 33.00% |
| EPS Basic | 27.89% | 61.22% | 77.61% | 60.40% | 36.45% |
| Normalized Basic EPS | 28.57% | 57.75% | 72.80% | 55.96% | 31.52% |
| EPS Diluted | 27.89% | 61.22% | 77.61% | 60.40% | 36.45% |
| Normalized Diluted EPS | 28.57% | 57.75% | 72.80% | 55.96% | 31.52% |
| Average Basic Shares Outstanding | 84.50% | 73.37% | 60.57% | 42.05% | 22.35% |
| Average Diluted Shares Outstanding | 84.50% | 73.37% | 60.57% | 42.05% | 22.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |